Press Releases
Laryngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019 | PRLog
Laryngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019. Laryngeal Cancer Therapeutics Market is Forecast to Show Slow Growth Until 2019 - PR11793534
Abbott to Present Broad Spectrum of Compelling Data for HUMIRA® (Adalimumab) at American College of
Abbott to Present Broad Spectrum of Compelling Data for HUMIRA < sup > ® < /sup > (Adalimumab) at American College of Rheumatology Annual Scientific Meeting
Generic & Biosimilar Opportunities with Respect to Multi-Therapy Drugs Reviewed in New Report
As used here, the term multi-therapy drug refers to any drug that has either been approved for, or is in clinical development for, more than one distinct indication during its lifecycle. Having established their usefulness in a number of indications, many of these drugs benefit from a wide patient
GP Pharm Expands its Pharmaceutical Line Against Advanced Colorectal Cancer with Oxaliplatin and
Home Products & Services Contract Manufacturing GP Pharm Press Release Company Details White Papers Press Releases Regional Offices Contact Company GP Pharm Expands its Pharmaceutical Line Against Advanced Colorectal Cancer with Oxaliplatin and Irinotecan 300mg and 500mg Email Article Print 30
Teva UK Limited Launches Temozolomide Capsules - Yahoo! Finance
CASTLEFORD, England, March 31, 2010 /PRNewswire/ -- We are pleased to announce the launch of temozolomide available in 5mg, 20mg, 100mg, 140mg, 180mg and 250mg
Medical News: Targeted Agent Tops Chemo for Selected NSCLC - in Hematology/Oncology, Lung Cancer
Lung cancer patients selected by mutation status had a 50% improvement in progression-free survival (PFS) when treated with gefitinib (Iressa) compared with cisplatin, data from a randomized clinical
Pharmacyclics, Inc. - Pharmacyclics Reports Recent Developments and Financial Results for Fiscal
Print Email PDF Add to Briefcase « Previous Release Pharmacyclics, Inc. February 4, 2011 Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 SUNNYVALE, Calif. , Feb. 4, 2011 /PRNewswire/ --
EFFECTIVE TREATMENT FOR SICKLE CELL UNDERUSED BY DOCTORS
Uncertainties about proper use and possible long-term effects of hydroxyurea in the treatment of sickle cell anemia may be wrongly influencing doctors to avoid prescribing it to those in serious need, according to results of a literature review by specialists at Johns Hopkins.
Myriad Genetics, Inc. - Myriad Genetics Sponsors Clinical Trial in Pancreatic Cancer
Myriad Genetics, Inc. Logo Print Print page Email Email page PDF Download PDF Add to Briefcase « Previous Release | Next Release » Myriad Genetics Sponsors Clinical Trial in Pancreatic Cancer Study May Lead to New Personalized Medicine Product Salt Lake City, October, 24,
Rhabdomyosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019 | PRLog
Rhabdomyosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019. Rhabdomyosarcoma Therapeutics Market Forecast to Show Slow Growth until 2019 - PR11788267
Refine by Content Type:
Refine by Source:
- www.prlog.org (22)
- ir.pharmacyclics.com (11)
- www.prweb.com (7)
- www.abbott.com (5)
- www.medpagetoday.com (4)
- investor.myriad.com (2)
- finance.yahoo.com (1)
- www.hopkinsmedicine.org (1)
- www.pharmaceutical-technology.com (1)
